Antipsychotic medication prescribing trends in a tertiary care hospital
Riyaz Ahmed Siddiqui*, Tanaji Ramaji Shende, Harshal Murlidhar Mahajan, Archana Borkar

ABSTRACT
Background: In psychiatric practice, antipsychotic drugs are widely used group of drugs. Numbers of drugs are available in this group with diverse type of mechanisms and efficacy/safety profile. The objective of the study was to identify the prescription pattern of antipsychotic drugs in the centre for determination of current trends.

Methods: The retrospective study was conducted at NKP Salve Institute of Medical Sciences and Research Centre, Nagpur, Hospital, Maharashtra, India case record files of the department of psychiatry for the year 2014-2015 were analysed for a total of 300 cases. Antipsychotic drugs received by the patient for psychiatric disorders like schizophrenia, mood disorders (major depression or mania) with psychotic features, substance induced psychosis, dementia and delirium with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorders etc. were noted and analysed for prescription pattern of antipsychotic drugs.

Results: Out of 300 cases that were analysed, olanzapine was the most commonly used antipsychotic drug i.e. in 51% of patients followed by risperidone in 23% and quetiapine in 13% of patients. Other drugs used were aripiprazole in 6%, clozapine in in 5.3%, i-loperidine in 5%, trifluperazine in 2% and triflupromazine in 1% of patients. Injectable haloperidol and the anticholinergic promethazine were used as on required basis.

Conclusions: Atypical antipsychotics are more commonly used as compared to the typical ones. Atypical antipsychotics like olanzapine, risperidone and quetiapine are preferred because of their lesser propensity to cause extrapyramidal adverse effects and they also helps in improving negative symptoms of schizophrenia.

Keywords: Atypical antipsychotic, Extrapyramidal adverse effect, Neuroleptics

INTRODUCTION
Antipsychotics are a class of agents which are able to reduce psychotic symptoms in a wide range of conditions like schizophrenia, bipolar disorder, psychotic depression, senile psychosis, various organic psychosis and drug induced psychosis. Antipsychotic prescription patterns are fundamentally different across countries and even regions due to variations in factors including health care policies, availability and cost of drugs, psychiatric training and preferred treatment modalities. Psychosis is a symptom of mental illnesses characterized by a distorted or non-existent sense of reality. Psychotic disorders have different etiologies, each of which demands a unique treatment approach. Currently a large number of atypical antipsyhotics available in the market are endorsed as better option for treating schizophrenia than the typical antipsychotics. Medical aspects focus on the need to balance between the risk and the benefits. The benefits are assessed on the basis of drug efficacy in preventing, relieving and curing diseases or their symptoms and complications. Potential risks include short term and long term adverse effects.

Application of pharmacoepidemiological studies often reveals the large differences that exist between the conditions of premarketing trials (done on a limited sample population) and those of actual practice several years into the market life of a pharmaceutical product. Clinical trial data must therefore be complemented by measurement of any eventual distortions and estimation of the real-life effectiveness and safety of the medicines.
Data from different parts of the world indicate increasing prescriptions for drugs used for mental disorders, particularly antidepressants and antipsychotics. Studies of antipsychotic prescribing show increases over the past two decades in a variety of countries. The rapidly expanding field of psychopharmacology is challenging the traditional concepts of psychiatric treatment and research, and is constantly seeking new and improved drugs to treat psychiatric disorders. In this way, psychiatrists are continuously exposed to newly introduced drugs that are claimed to be safe and more efficacious. Although psychotropic medications have had a remarkable impact on psychiatric practice that legitimately can be called revolutionary, their utilization and consequences on real life effectiveness and safety in actual clinical practice need continuous study.

Availability of wide variety of antipsychotic drugs and globally their different pattern of prescription indicates that different regional population need different antipsychotic drug. Therefore this study was undertaken to analyse the prescription pattern of various antipsychotic drugs in this part of central India hospital so that the current trend can be identified which will be useful for the management of psychiatric disorders.

METHODS

It is a retrospective record based study that is carried out at NKP salve institute of medical sciences and RC, Nagpur. Ethical committee permission was obtained prior to the study. Hospital case record files of the department of psychiatry for the year 2014-2015 were analysed for a total of 300 cases. The various antipsychotic drugs received by the patient like typical antipsychotic and atypical antipsychotic for various psychiatric disorders like schizophrenia, mood disorders (major depression or mania) with psychotic features, substance induced psychosis, dementia and delirium with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorders etc. were noted. Data was recorded in case record from and analysed using Microsoft excel program.

RESULTS

We have analysed a total number of 300 hospital case record files of the department of psychiatry of the year 2014-2015. The various antipsychotic drugs prescribed to the patients like typical antipsychotic and atypical antipsychotic for various psychiatric disorders like schizophrenia, mood disorders (major depression or mania) with psychotic features, substance induced psychosis, dementia and delirium with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorders etc. were noted. Olanzapine was the was the most commonly used antipsychotic drug i.e. in 51% of patients followed by resperidone in 23% and quetiapine in 13% of patients. Other drugs used were aripiprazole in 6%, clozapine in in 5.3%, Iloperidine in 5%, trifluperazine in 2% and triflupromazine in 1% of patients. Injectable haloperidol and the anticholinergic promethazine were used as on required basis.

Table 1: Depicting drug received by the patient and their percentage.

<table>
<thead>
<tr>
<th>Drug received</th>
<th>No. of patients</th>
<th>% of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olanzapine</td>
<td>153</td>
<td>51</td>
</tr>
<tr>
<td>Resperidone</td>
<td>69</td>
<td>23</td>
</tr>
<tr>
<td>Quetiapine</td>
<td>39</td>
<td>13</td>
</tr>
<tr>
<td>Aripiprazole</td>
<td>18</td>
<td>6</td>
</tr>
<tr>
<td>Clozapine</td>
<td>16</td>
<td>5.3</td>
</tr>
<tr>
<td>Ilobril</td>
<td>15</td>
<td>5</td>
</tr>
<tr>
<td>Trifluperazine</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>Triflupromazine</td>
<td>3</td>
<td>1</td>
</tr>
</tbody>
</table>

Figure 1: Depicting drug received by the patient and their percentage.

DISCUSSION

In the present study olanzapine was the most commonly used antipsychotic drug i.e. in 51% of patients followed by resperidone in 23% and quetiapine in 13% of patients. Other less commonly used drugs were aripiprazole in 6%, clozapine in in 5.3%, Iloperidine in 5%, trifluperazine in 2% and triflupromazine in 1% of patients. Centorrino et al evaluated medication use in all McLean Hospital in patients treated with antipsychotic drugs during 3 months in 1998, the ranking of antipsychotic use for the 349 patients was olanzapine in 36%, risperidone 17%, quetiapine 17%, perphenazine 10%, clozapine 6%, and haloperidol 6%; other typical neuroleptics were used for 3% or less of the patients. Banerjee et al in their study at a teaching hospital in schizophrenic patients found that olanzapine was the commonest antipsychotic drug prescribed in 34.3%, followed by haloperidol in 28.6%, combination of haloperidol and olanzapine 12.4%, risperidone 17.4%, clozapine 3.8%, quetiapine 2.4% and aripiprazole 1% (atypical antipsychotics ) respectively. Bln et al carried out cross sectional survey by a random sample of 61 public and 112 private psychiatrists who registered for one month all schizophrenic adult outpatients treated with a neuroleptic drug. Psychiatrists
included 934 patients in the public care setting and 927 patients in the private care setting. An atypical neuroleptic was prescribed for 63.0% of patients and a classic neuroleptic for 49.7%, an association of neuroleptics for 22.0% and in both settings, the most prescribed neuroleptics were olanzapine (28.0%) and risperidone (18.6%). Also Deshmukh et al in a prospective, cross sectional and observational study over 22 weeks on 515 newly diagnosed psychiatric out patients observed that apart from antidepressants (60.4%), in antipsychotics category, olanzapine use was highest (26.6%). Piparva et al in a prospective cross sectional study of 6 months duration in outdoor patients (OPD) of the psychiatry department found that atypical antipsychotic drugs (43.83%) were prescribed more frequently than the typical antipsychotic drugs (26.32%). Ghosh et al in a cross-sectional, unincet study in the psychiatry outpatient department (OPD), of a tertiary care, medical college and hospital found that atypical antipsychotics are prescribed more commonly than typical antipsychotic and among the atypical antipsychotics olanzapine is most commonly prescribed. Dutta et al in their study on psychotropic drug use among depression patients attending private psychiatric practitioners found that SSRIs (39.17%) were the most commonly prescribed class of antidepressants and among patients, 18.48% antipsychotics were prescribed to patients; olanzapine and risperidone were the most commonly prescribed. Trihexyphenidyl was the most common anticholinergic prescribed. Grohmann et al in their study analyse data on drug use in 1995 and 2001 assessed at two reference days per year and per hospital within the drug safety program AMSP were compared for 10 hospitals found that atypical neuroleptics (NL) were used in 59.9% of patients on NLs in 2001 (16.7% in 1995), most frequently olanzapine, risperidone, clozapine, and quetiapine, in this order. 39% of patients still received typical NLs in antipsychotic indication (77.1% in 1995), and 30.8% received typical hypnosedative NLs (38.1% in 1995). All the above findings suggests that atypical antipsychotics like olanzapine and risperidone are the commonly prescribed drugs as compared to the atypical ones which is in accordance with our study. Increase use of atypical antipsychotic agents like olanzapine, risperidone, quetiapine and ziprasidone can be because they have provided a better control of symptoms and reduced the chances of adverse effects especially the extrapyramidal ones in contrast with typical antipsychotic drugs and also proved to be better in improving negative symptoms, cognitive dysfunction and also efficacious in antipsychotic resistant cases.7

Doshi et al in their cross-sectional, prospective drug utilization study in outdoor patient of Psychiatry in a tertiary care hospital among 600 patients, found that most common disorder was depression 208 (34.66%) followed by schizophrenia 192 (32.00%), and the most common prescribed drugs are diazepam 74.55%. Next in line are risperidone 59.76%, olanzapine, 40.23%, trihexyphenidyl 43.75% and clozapine 13.01%. Iliyaz et al in a retrospective cross sectional study conducted at Hyderabad, analysed 500 prescription of patients with neuropsychiatric disorder observed that risperidone was 40.8% prescribed, olanzapine 4.02%, quetiapine 8.62%, amisulpiride 4.02% and aripiprazole 0.57% prescribed. Also in anxiety disorder as a concomitant medicine risperidone was prescribed in 29.07% and olanzapine in 3.54%. In these above two studies though atypical antipsychotics were more commonly prescribed but risperidone was more commonly prescribed than olanzapine. Also Thakkar et al in a drug utilization study 600 prescriptions for different psychiatric disorders found that most commonly prescribed drugs for schizophrenia, bipolar disorders, depression and anxiety disorders were trifluoperazine + trihexyphenidyl (63.9%), carbamazepine (17.2%), amitriptyline (34.9%), and diazepam (23.8%), respectively. In this one study combination of typical antipsychotic (trifluperazone) with an anticholinergic (trihexyphenidyl) was used more commonly than atypical antipsychotic is not in accordance with our study findings.8

The FDA has approved the use of selected antipsychotic medications for children and adolescents for treatment of severe conduct problems that are resistant to other forms of treatment. Specific child psychiatric disorders include Tourette’s syndrome and behavioural symptoms associated with autistic disorder, childhood schizophrenia, and bipolar disorder. National guidelines do recommend antipsychotics for the relatively rare condition of psychotic depression and as a possible intervention for treatment-resistant cases of severe depression and OCD. In clinical practice, these agents may be prescribed ‘off-label’ for patients who do not have a diagnosis of SMI (severe mental illness) in their clinical notes. They are sometimes used to augment antidepressants in complex or treatment-resistant cases of OCD, anxiety and personality disorders. For borderline personality disorder short-term treatment with antipsychotics (up to a week) may be beneficial in crisis situations or when comorbid psychotic symptoms occur.9

CONCLUSION

Antipsychotics are one of the commonly used medications for schizophrenia and other psychiatric disorders. Of the antipsychotics, atypical antipsychotics like olanzapine, risperidone and quetiapine were most commonly used. Use of typical antipsychotics is declining. Atypical agents are preferred because of their better symptoms control and reduced chances of the extrapyramidal adverse effects and also in improving negative symptoms, cognitive dysfunction and also efficacious in antipsychotic resistant cases.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee
REFERENCES


